Results 191 to 200 of about 3,314,611 (329)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

The Oral Microbiota: Implications in Mucosal Health and Systemic Disease-Crosstalk with Gut and Brain. [PDF]

Cells
Miranda V, Laarej K, Cavaliere C.
europepmc   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Measuring Opsonic Phagocytosis via Fcγ Receptors and Complement Receptors on Macrophages

Current Protocols in Immunology, 2011
D. Mosser, Xia Zhang
semanticscholar   +1 more source

Complement 5a (C5a), complement 5a receptor (C5aR; CD88), complement 5a–like receptor (C5L2) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Gut complement system: a new frontier in microbiota-host communication and intestinal homeostasis. [PDF]

J Clin Invest
Tian X, Zhang L, Qian X, Peng Y, Chen F, Bengtson S, Wang Z, Wu M.   +7 more
europepmc   +1 more source

Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Cancer Research, 2018
Jeff W. Kwak, J. Laskowski, Howard Y. Li, M. McSharry, Trisha R Sippel, Bonnie L. Bullock, Amber M. Johnson, J. Poczobutt, A. Neuwelt, S. Malkoski, M. Weiser-Evans, John D Lambris, E. Clambey, J. Thurman, R. Nemenoff   +14 more
semanticscholar   +1 more source

The McCance Brain Care Score and Mortality: Evidence From a Large‐Scale Population‐Based Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives This study aimed to examine the relationship between the McCance Brain Care Score (BCS) and mortality in the general population. Methods We conducted a prospective, population‐based cohort study using data from the UK Biobank. Participants with complete data enabling calculation of BCS and full mortality information were included ...
Zhiqiang Xu, Xiaoxiao Wang, Nan Li
wiley   +1 more source

Inhibition of Complement Will Substantially Reduce the Anemia of Malaria. [PDF]

J Immunol Res
Taylor RP, Lindorfer MA.
europepmc   +1 more source